Pfs25-IMX313/Matrix-M1 / University of Oxford - LARVOL DELTA

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. (clinicaltrials.gov) - P1 | N=34 | Terminated | Sponsor: University of Oxford | N=52 ➔ 34 | Trial completion date: Mar 2023 ➔ Feb 2024 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2023 ➔ Feb 2024; Due to significant delays in receiving local regulatory approval to extend the shelf-life of the IMP.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Malaria

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. (PubMed, Malar J) - "Here, the immunological mechanisms underlying malaria transmission blocking, status of Pfs25-based vaccines are viewed, as well as approaches and capacity for first in-human evaluation of a transmission-blocking candidate vaccine Pfs25-IMX313/Matrix-M administered to semi-immune healthy individuals in endemic settings. It is concluded that institutions in low and middle income settings should be supported to conduct first-in human vaccine trials in order to stimulate innovative research and reduce the overdependence on developed countries for research and local interventions against many diseases of public health importance."

Journal • Review • Immunology • Infectious Disease • Malaria

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. (clinicaltrials.gov) - P1; N=52; Recruiting; Sponsor: University of Oxford; Not yet recruiting ➔ Recruiting

Enrollment open • Preclinical • Infectious Disease • Malaria

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: University of Oxford; Trial completion date: Apr 2022 ➔ Nov 2022; Trial primary completion date: Apr 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine (clinicaltrials.gov) - P1; N=1; Terminated; Sponsor: University of Oxford; Recruiting ➔ Terminated; Delays caused by Covid-19

Clinical • Trial termination • Infectious Disease • Malaria

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: University of Oxford; Initiation date: Apr 2020 ➔ Nov 2020

Trial initiation date • Infectious Disease • Malaria

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: University of Oxford

New P1 trial